Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial
Nelson, Mark; Abhayaratna, Walter; Grimm , R; ASPREE Investigator Group, _; Pressman, G.; Margolis, K.; Volpi, E.; McNeil, John J; Reid, Christopher M; Nelson, MR.; Stocks, N.; Ames, D; Beilin, Lawrence J.
Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. ASPREE will examine whether the potential primary prevention benefits of low dose aspirin outweigh the risks in older healthy individuals. Our primary hypothesis is that daily oral 100. mg enteric-coated aspirin will extend a composite primary endpoint termed 'disability-free life' including onset of dementia, total mortality, or persistent...[Show more]
|Collections||ANU Research Publications|
|Source:||Contemporary Clinical Trials|
|01_Nelson_Study_design_of_ASPirin_in_2013.pdf||276.7 kB||Adobe PDF||Request a copy|